Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
14. September 2021 22:23 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
14. September 2021 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that...
Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.
26. August 2021 07:30 ET
|
Cerecor Inc.
Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates...
Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
02. August 2021 16:01 ET
|
Cerecor Inc.
Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including...
Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
02. August 2021 07:30 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
26. Juli 2021 16:01 ET
|
Cerecor Inc.
Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF...
Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
23. Juni 2021 07:30 ET
|
Cerecor Inc.
ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
07. Juni 2021 07:00 ET
|
Cerecor Inc.
An initial tranche of $20 million drawn at the loan closingFunds ongoing clinical development of key investigational product candidatesFinancing provides flexibility and extends runway through...
Cerecor to Participate in Upcoming Investor Conferences
17. Mai 2021 07:00 ET
|
Cerecor Inc.
ROCKVILLE, Md. and CHESTERBROOK, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization...
Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
13. Mai 2021 07:00 ET
|
Cerecor Inc.
Announced CERC-002 received Fast Track Designation from the U.S. Food and Drug Administration, following positive Phase 2 clinical trial for the treatment of patients hospitalized with COVID-19...